Back to News
Jan 9, 2026 8:50 AM

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition.

Psoriatic arthritis is linked to psoriasis (a condition that affects skin and nails). It causes joint pain, stiffness, and a skin rash.

At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for superiority to Taltz monotherapy.

The company on Thursday said that TOGETHER-PsA is the first controlled study to evaluate an incretin therapy used with ...